List of Biotech, Pharmaceutical & Life Sciences companies in Singapore - 44

4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our coveted 🧬genomic testing portfolio assesses the tumour genomic alterations by NGS from Tissue or Liquid biopsy for Somatic Mutation Analysis and Germline Mutation Testing for Hereditary and Familial Cancer from peripheral blood to personalize patient care in Oncology. 4baseCare is backed by a highly experienced Advisory board who are leaders in genomics and technology. Among them is Lip Bu Tan, Chairman of Walden International and advisor to Yali Capital, which has invested in 4baseCare. Also on the board is Francis deSouza, a Silicon Valley tech veteran and former CEO of Illumina, who brings over 30 years of expertise in genomics, technology, and healthcare. Milestones - 4baseCare’s journey has been marked by significant milestones in both funding and growth. The company has raised $6 Million in Series A funding led by Yali Capital with participation from Mathew Cyriac. In March 2021, 4baseCare had raised $2 Million in led by Mount Judi Ventures, growX ventures, Season Two Ventures, First In Ventures, and other angel investors. 4baseCare’s test has made a significant impact in Southeast Asia, with over 10,000 cancer patients taking the test. 4baseCare has collaborations with more than 300 oncologists in India. This growing network with oncologists and leading hospitals in India ensures that more patients are able to opt for personalized cancer care.

Aevice Health Pte Ltd is a Singapore-based MedTech spin-off from Nanyang Technological University at the forefront of addressing chronic respiratory disease, one of the generation's biggest healthcare challenges. The company's non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time, so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients' health and track their responses to treatment plans easily from the Aevice analytical platform. In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives. More information about the company can be found at www.aevice.com.

Albatroz Therapeutics is a pre-clinical stage biotech company developing therapeutic antibodies and ADCs to treat solid tumours and arthritis, based on its proprietary position over a novel target critical to ECM degradation.

Allozymes is a fast-growing biotechnology company that applies its proprietary ultra-high-throughput platform technology to rapidly develop novel enzymes and unlock the bioeconomy across sectors. Leveraging this ultra-high screening power, Allozymes aims to build the largest enzyme data library in the world to address the current and future needs of building robust biosolutions.

Auristone is an Asian-based epigenomic profiling company powered with data analytics capabilities and extensive epigenomic know-how. We use our comprehensive portfolio of Asian epigenomic database to power data-driven drug and biomarker discoveries. EPI-Call™ is our Flagship second generation Next Generation Sequencing (NGS) test. In addition to genomic information (DNA-seq), EPI-Call™ further provides epigenomic information around the tumour micro-environment and predicts patient response to immunotherapy. EPI-Call™ is the pragmatic choice to aid physicians in deciding the best treatment option for their patients. We are committed to supporting clinical and academic epigenomic research, and moving such research outcomes into the clinical setting. Driven by our aspiration to improve the quality of life for patients through better treatment, we are continuously seeking ways to bring our technologies to our clinical and academic partners. For more information on the company, drop us a line at enquiry@auristone.com or visit our website at www.auristone.com.

Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions. At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and development efforts. This cutting-edge platform empowers us to swiftly explore numerous linker and payload combinations alongside our proprietary antibodies. We further harness state-of-the-art technologies, including an exclusive payload library derived from an FDA-approved drug and site-specific conjugation methods. These innovations are strategically employed to enhance the safety and quality of our ADCs. With two potential best-in-class programs on track for clinical trials by 2025 and a third program making headway toward IND status, we are poised for significant value creation and breakthroughs in cancer therapeutics. Based in Singapore, we plan to expand our clinical development operations to the United States by 2024. Join us on our journey to transform cancer treatment and make a meaningful impact in biotechnology. Axcynsis is at the forefront of developing life-changing ADC therapies, and we invite you to be a part of our innovative and dedicated team as we pioneer the future of cancer therapeutics.

Biolidics – Bringing clarity to cancer Biolidics Ltd, formerly known as Clearbridge BioMedics, is a medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring. Biolidics has developed patented technology and solutions with the potential to serve as a platform technology for the diagnosis, prognosis, treatment selection and treatment monitoring of various types of cancers. The ClearCell® FX1 System by Biolidics is a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood. This allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells, providing a simple and minimally invasive alternative to tissue biopsies, which involve the surgical removal of tissue from a patient's body. Our patented award-winning microfluidic technologies have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post-cancer monitoring. The ClearCell® FX1 System has been installed in academic and research institutes, hospitals and laboratories across the world, including Singapore, China, Hong Kong, Japan, the US and certain EU countries. Biolidics is a spin-off from the National University of Singapore (NUS) / SMART MIT and is the first incubatee of Clearbridge Accelerator, a high-technology incubator backed by the Singapore Government's National Research Foundation (NRF). For more information, please visit www.biolidics.com.

Biosyngen is a cell therapy company focusing on unmet needs with technology targeting solid tumors and lymphoproliferative diseases. The company’s first-in-class products have entered into Phase I/II clinical trials for nasopharyngeal cancer (ODD and Fast-Track), lymphoproliferative disease and lung cancer. The company continues to enrich its pipeline with further IND submissions. Biosyngen drives its global strategy from the dual HQ in Singapore and Guangzhou. Leverages on the public-private biopharma ecosystem for the better cause. Committed to giving cancer patients a better chance to survive, our pipeline is enriched, covering other major indications which are on track for regulatory registration. Biosyngen seeks breakthrough in collaborations, particularly in translational R&D and clinical development. The company has positioned GMP cell therapy manufacturing facilities in two locations - in Singapore and Guangzhou covering global needs. To quicken drug development from bench-to-bedside, a parallel effort in the form of the Translational Medicine Centre is set up. It is public-private-partnership connecting stakeholders in R&D, Clinical Development, Hospitals, Pharma, Enterprises and Venture Capital.

BluMaiden Biosciences is a biotech therapeutics company operating in the USA and Europe. It leverages naturally occurring, human-derived small molecules to develop superior therapeutic solutions. Through its advanced computational platform, BluMaiden explores untapped chemical spaces within the human body, uncovering safer and biocompatible small molecule drug candidates. This innovative approach overcomes the limitations of traditional synthetic chemistry, driving groundbreaking treatments and transforming pharmaceutical drug pipelines.

CellResearch Corporation was founded in Singapore in 2002 by scientists with a keen interest and expertise in Cell Biology. In 2004, our scientists isolated Epithelial and Mesenchymal Stem Cells from the Umbilical Cord Lining Membrane. This novel and significant discovery was put up for intellectual property protection, and to date we have patents granted in multiple strategic key territories around the world. The umbilical cord lining membrane is now known to be the richest source of stem cells in the body, and both epithelial and mesenchymal stem cells are being researched intensively with collaborators all around the world to exploit their potential for downstream medical therapy. Considerable headway has already been achieved, and we have started USFDA Clinical Trials with our collaborators in the USA, leading to a therapy to accelerate wound healing.

Cerecin is a global healthcare company with almost 20 years of innovation and leadership in brain health. At Cerecin we think differently. We develop novel evidence-based solutions that help people; pharmaceuticals, medical foods, diagnostics, medical devices and e-health products. These solutions target conditions ranging from memory impairment to some of the most devastating neurological diseases.

Clearstatehelpshealthcare clients across different functions and roles, including research and development, strategic planning, marketing and sales, government affairs and new business development, to discover new opportunities and formulate evidence-based strategies.

Credo Diagnostics Biomedical develops, manufactures, and commercializes innovative, cost-effective, and rapid Molecular Diagnostic solutions at the Point-of-Care (POC) in the areas of human infectious diseases and animal health. At Credo Diagnostics Biomedical, we are conscious of the necessity to simplify processes and accelerate molecular testing at lower costs. We believe that effective rapid POC Molecular Diagnostics will redefine healthcare for both human and veterinary clinical management. By providing the right information, at the right time, and to the right people, we can improve the lives of billions of people and animals around the world. For any inquiries, please contact us at: service@credodxbiomed.com

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s national research and development agency in the public sector. CytoMed is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors.

DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University.

Emerald Clinical is a global clinical research organization (CRO) that specializes in end-to-end clinical trial management. Operating in over 70 countries, the company has completed more than 600 clinical trials, with a strong focus on Oncology and Cardio-Renal-Metabolic research. With over 20 years of experience, Emerald Clinical aims to mitigate clinical development risks through localized solutions and scientific leadership. The company offers comprehensive services, including protocol design, site selection, and regulatory compliance. It emphasizes predictable trial delivery and inclusive trial design, ensuring diverse patient populations are represented in research outcomes. Emerald Clinical serves over 100 biotech companies and six of the top ten pharmaceutical firms, leveraging its expertise and reputation for reliability. The leadership team, supported by an advisory committee of active researchers and clinicians, is dedicated to advancing clinical research with transparency and innovation.

Evive Biotech is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, Singapore, and China. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, Evive adopts a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house regulatory expertise and extensive international management experience. Through partnerships with industry, physicians, and regulatory authorities, we strive to bring revolutionary remedies to the global market quickly and efficiently to address unmet medical needs, making a real and lasting difference to patients and their families worldwide.

We are a preclinical stage AI drug discovery company with a mission to eliminate age-related diseases We use AI to build clinically relevant disease phenotypes in real-world human data and identify diseases with shared biology. Then WES-enabled genetic study on these phenotypes allows us to discover novel targets applicable to several indications at once. You can find our publications here: https://gero.ai/publications

HistoIndex is a digital pathology company based in Singapore, founded in 2010. It specializes in AI-driven, stain-free tissue analysis, focusing on disease assessment, particularly for fibrosis and liver-related conditions. The company utilizes its proprietary Second Harmonic Generation (SHG) imaging technology to provide high-resolution visualization of collagen and other structural proteins, enhancing the accuracy of pathology assessments. HistoIndex offers stain-free digital pathology services that detect and quantify fibrosis, inflammation, and other biomarkers in tissues such as the liver, kidney, and skin. Its AI image-analysis platforms support reproducible quantification of morphological features, which is beneficial for clinical trials and diagnostics. The company collaborates with research institutions and pharmaceutical companies to evaluate drug efficacy in various diseases, including metabolic dysfunction-associated liver conditions. With a global presence, HistoIndex operates imaging centers and maintains partnerships across multiple countries, including the US, UK, and India.

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. Sign up for our updates here: https://bit.ly/HMBDNews

Imagene Labs is a healthcare technology company that provides an enterprise genetics analysis platform for creating personalized products and services based on individuals' DNA insights.

Entrepreneur led and science backed, 𝐈𝐍𝐄𝐗 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞 is one of Asia’s fastest growing molecular diagnostics developers and medical laboratory operators. Founded by veteran maternal fetal medicine specialists, INEX is uniquely positioned to identify and address clinically unmet needs within the fetal health and women’s oncology landscape, with a broad commercial portfolio of validated tests and 49 key patents. Through our wholly owned subsidiary iGene Laboratory Pte Ltd, INEX operates a state of the art Next Generation Sequencing Laboratory that provides diagnostic testing, clinical research (CRO) and infectious testing services. The company has been recognised globally with a number of accolades and awards including from Frost & Sullivan, the World Intellectual Property Organisation (WIPO), The Straits Times – Singapore’s Fastest Growing Companies, the Financial Times ranking of 500 of Asia Pacific’s Fastest Growing Companies and the Business Times KPMG Enterprise 50 award, recognising the 50 most enterprising Singapore companies. For more information please visit: www.inex.sg

Invitrocue Limited is a biotechnology company based in Singapore, founded in 2012. The company specializes in advanced 3D cell-based models and personalized oncology solutions, operating globally with a presence in Australia, China, Hong Kong, and Germany. Invitrocue offers a range of services, including the Onco Patient-Derived Organoid (PDO) Test, which uses patient-derived tumor cells to tailor cancer treatments. Their 3D CelluSponge Technology provides a scaffold-based system for drug metabolism studies, toxicology assessments, and infectious disease modeling. Additionally, they offer customized services for disease modeling and assays, focusing on respiratory diseases and liver infections, as well as digital pathology and medical imaging to support drug testing and organoid analysis. The company collaborates with industry networks to develop preclinical models, enhancing drug discovery and therapeutic outcomes.

JN Medsys is a people-centered life science company driven by the desire to make complex genomic tools accessible to more people. Through a relentless commitment to innovation, we aim to deliver simplified solutions that achieve improved performance at better affordability. The Clarity digital PCR is the epitome of this vision. It brings digital PCR analysis to the next level by significantly reducing its preparation time and simplifying its workflow. With digital PCR this fast and easy, the choice is now clear. Choose Clarity for your digital PCR needs.

Juniper Biologics is birthed on the basic premise that access to healthcare is a birthright. We are a science-led healthcare company focused on delivering novel therapies to improve the health and quality of life of patients everywhere by building a growing presence in oncology, rare/orphan diseases and gene therapy. Juniper Biologics was founded on a vision to create a pharmaceutical business that is both agile and innovative. This includes a commitment to providing treatments for unmet needs focused on specialist therapy areas in which we can make the most difference. Our purpose is clear: to do all that we can to change the treatment landscape and address the unmet medical needs of patients, and to do it as quickly as possible. Through bold and transformative science, we’re creating possibilities that have the potential to become the next generation of life-changing medicines. This is just the beginning of our story… and we are just getting started.

Lion TCR is a clinical-stage biotechnology company dedicated to the continued development and commercialization of our TCR-T therapy.

MediSix Therapeutics - We are a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Our technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Our programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.

Founded in 2016, MegaRobo is a national high-tech enterprise, headquartered in Beijing, with branches in Shenzhen, Shanghai, and Suzhou; the team size is over 300 persons, with R&D personnel accounting for 60%. Focusing on R&D and the application of robot and intelligent Internet of things, MegaRobo has a number of core technologies that are competitive in the world and has applied for over 200 invention patents, which have passed the IOS9001 Quality Management System Certification. Based in China and facing the world, MegaRobo unremittingly provides industry-leading, efficient, and reliable automation solutions for the life sciences, smart retail, and lightweight manufacturing.

Multidimensional Health Intelligence Platform for digital powered care delivery Mesh Bio is a fast growing digital health startup focused on addressing the growing challenges in care delivery. Mesh Bio develops AI powered clinical decision support, analytics and automation solutions for healthcare providers to transform healthcare delivery with digital solutions. At Mesh Bio, we actively build an environment for personal excellence and career growth. We encourage diversity of experiences/backgrounds and want team members to thrive in their domain of professional expertise.

Micropoint Technologies Pte Ltd was established in 2008 by its founder, Mr. Chee Lim. The company is a spin-off from the Institute of Materials Research & Engineering, wherein he worked for seven years developing the microneedle technology.

Mirxes is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses across the care continuum. We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide. Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey. MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics. Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases. We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.

NalaGenetics was built with the passion to make preventive, DNA-based precision healthcare accessible to as many people as possible. Specifically, catalyzed by the founders' personal experiences of problematic medication side effects and knowledge of what genetic testing can offer, NalaGenetics aims to help people achieve better nutrition and prescription medication outcomes by analyzing their unique DNA. Today, NalaGenetics' solutions are trusted by a growing number of healthcare providers, laboratories, insurers, and corporates in Asia and Europe. We have also won government grants and mandates to carry out genomic research projects from the Government of Singapore and others. These achievements reflect the company's exceptional standards and depth of research as a scientist-led company, along with a commitment to delivering best-in-class genomic solutions. Find out more about us at www.nalagenetics.com

The National University of Singapore is a national research university in Singapore.

About NSG BioLabs NSG BioLabs is Singapore's leading and largest co-working BSL-2 laboratory designed specifically to hatch revolutionary biotechnology ventures. With large laboratory benches, several state-of-the-art tissue culture suites, an extensive list of shared core equipment, and a group of very carefully selected tenants and partners in its sites, NSG BioLabs and NSG Ventures is a complete global life sciences incubation ecosystem

Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery

We are a molecular life science company dedicated to advancing human health through innovation. By designing and building breakthrough molecular platforms that are both accessible and best-in-class, One BioMed is providing biomedical researchers and clinicians with unprecedented access to cutting-edge tools.

PairX is pioneering the development of next-generation cancer-selective biologics by identifying novel, highly prevalent, tumor-selective cell surface variants. Our biology-driven approach reveals a new class of therapeutic targets that can be paired with a variety of optimal therapeutic modalities. Founded on IP exclusively licensed from Duke-NUS Medical School, Singapore, PairX is advancing a robust pipeline of potential first- and best-in-class tumor-selective therapies targeting prevalent cancers in substantial patient populations.

Peptobiotics is a synbio startup that develops livestock disease prevention biotechnology. By leveraging advances in human medicine and synthetic biology, they are creating a new class of feed additives that can maximize animal health.

RWDC Industries is on a mission to replace petroleum-derived materials with safe, sustainable alternatives. We have developed technology to harvest outputs of a microbial fermentation process using plant-based oils that produces a naturally occurring biodegradable polymer called PHA (or polyhydroxylalkanoate). PHA's are biopolymers naturally produced by microbial fermentation of plant-based oils or sugar. RWDC's PHA — Solon — is certified by TÜV Austria to be fully biodegradable in soil, water and marine conditions. Solon is 100% biodegradable with no toxic residue. Solon is a global solution to today's plastic waste management challenge, and it's an ideal material for replacing petroleum-derived, single-use plastics — such as cutlery, cups, bags, plates and bowls. Solon safely biodegrades in natural environments, leaving absolutely no harmful remains or byproducts.

Established and headquartered in Singapore, SCG Cell Therapy Pte Ltd (SCG) is a leading biotechnology company that combines regional advantages in Singapore, China and Germany, to cover the entire value chain from innovative drug research and discovery, manufacturing, clinical development and commercialization. SCG specializes in the development of novel immunotherapies in infections and its associated cancers. The company targets the most common cancer-causing infections: helicobacter pylori, human papillomavirus, and hepatitis B, and develops a broad and unique pipeline of T cell therapies, antibodies, and therapeutic vaccines against infections and to prevent and cure its associated cancers. SCG collaborates with leading scientists and researchers to bring first-in-class medical products/technologies to enhance innovation in medical product development.

SDT Molecular is a Singapore-based company with the vision of bringing advanced technologies and innovative products to healthcare professionals, hospitals and clinical laboratories.

SABio is a biotechnology company that offers quality custom-made RNA oligos/siRNAs, peptides, ready-made antibodies, custom antibody production services, and more.

At TurtleTree, we are pioneering the future of health with our breakthrough product, LF+: the world’s first vegan lactoferrin created through cutting-edge precision fermentation technology. Lactoferrin, a bioactive milk protein, enhances the nutritional profile of a wide range of food and health products. From plant-based alternatives and traditional foods to skincare and cosmetics, LF+ provides exceptional health benefits. Our innovative process not only contributes to human health but also ensures that animals can live carefree, happier lives. As we continue to push the boundaries of food science, we are seeking out partners and investors to join us as we create a healthy and sustainable future. Join the health revolution. Where Nutrition Meets Humanity.